Rybelsus is typically initiated at 3 mg daily for one month, then increased to 7 mg, with a possible further increase to 14 mg if additional glycaemic control is needed
However, real-life analyses indicate a higher discontinuation rate, of approximately 70% stopping within 2 years, especially in non-diabetic patients (112, 113)
Each additional receptor target appears to enhance efficacy but also changes the side effect profile and mechanism of action
Interestingly, the dual agonist tirzepatide has shown efficacy in neuroprotection, by counteracting hyperglycemia and insulin resistance-related effects at the neuronal level ( Also triple agonists have demonstrated to possess anti-neurodegenerative properties, indicating a potential for treating Alzheimers disease by reducing neuroinflammation and oxidative stress, enhancing neuronal health and viability, and minimizing glutamate excitotoxicity (Kopp et al., 2022)
Beans and lentils pack tremendous fiber into relatively small portions